Quest Diagnostics Inc Receives a Buy from Canaccord Genuity

By Carrie Williams

In a report issued on September 11, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Quest Diagnostics Inc (NYSE: DGX), with a price target of $118. The company’s shares closed yesterday at $107.53, close to its 52-week high of $112.97.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 14.6% and a 58.6% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Orasure Technologies.

Quest Diagnostics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $111.88.

The company has a one year high of $112.97 and a one year low of $79.12. Currently, Quest Diagnostics Inc has an average volume of 802.3K.

Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quest Diagnostics, Inc. is engaged in providing diagnostic testing, information and services that help patients, physicians and others to make better healthcare decisions. The company operates through two segments: Diagnostic Information Services and Diagnostic Solutions.